Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our result suggests that co-targeting of Ephs, TRKs and the c-Kit pathway may be effective at eliminating the PI3K-independent CSC population, thereby providing potential targets for future development of a novel anti-CSC therapeutic approach for HNSCC patients, particularly for patients with PIK3CA amplification.
|
31600013 |
2020 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
BYL719 is an α-specific PI3K inhibitor that is synergistic and efficacious when combined with cetuximab, an FDA-approved radiosensitizing agent in the treatment of HNSCC.
|
31678634 |
2020 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
The most common abnormalities downstream from EGFR in HNSCC are in the PI3K pathway, activated via loss of expression of the regulator PTEN, or via PI3K mutation.
|
30926065 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study assessed the maximum tolerated dose (MTD) of the PI3K inhibitor buparlisib given concurrently with cetuximab in recurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
|
31486207 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
NOTCH1 inhibition or knockout increased <i>NOTCH1</i><sup>WT</sup> HNSCC sensitivity to PI3K/mTOR inhibition.
|
30770351 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinoma.
|
31235758 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we examined the responses of a large panel of patient-derived HNSCC cell lines to various combinations of PI3K and EGFR inhibitors, including EGFR agents with varying specificity and mechanistic characteristics.
|
30858165 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Whereas overexpression of RICTOR reduced susceptibility of HNSCC tumor cells to PI3K inhibition, genetic ablation of RICTOR using CRISPR/Cas9 sensitized cells to PI3K inhibition, as well as to EGFR inhibition and cisplatin treatment.
|
31393061 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
ZNF703 over-expression is associated with copy number variation and this over-expression may activate PI3K/Akt signalling pathway in HNSCC.
|
31574205 |
2019 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
In present study, we investigated the resistant mechanisms and potential combination therapeutic strategy to overcome adaptive resistance to PI3K inhibitor in HNSCC.
|
28945228 |
2018 |
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The poor prognostic value of GOF <i>TP53</i> variants and mTOR pathway upregulation was confirmed in the TCGA SCCHN cohort.<b>Conclusions:</b> Our study demonstrates a link of intratumoral heterogeneity and clonal evolution as important mechanisms of drug resistance in SCCHN and establishes mutant GOF <i>TP53</i> variants and the PI3K/mTOR pathway as molecular targets for treatment optimization.<i></i>.
|
29061642 |
2018 |
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Tissue arrays showed that PI3K p110α levels correlated with YAP nuclear localization in HNSCC tumors.
|
29598951 |
2018 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Most importantly, one mechanism was found that PF-03084014 alone could activate the PI3K/AKT signalling, the downstream of EGFR signalling, and Erlotinib alone could activate the intracellular domain of Notch1 (NICD), while combined treatment of PF-03084014 and Erlotinib suppressed the HNSCC growth.
|
29232766 |
2018 |
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
HRAS mutant cells are resistant to PI3K inhibition and our findings suggest the involvement of a signalling intersection of the MAPK and PI3K pathways at the level of ERK-TSC2, leading to persistent mTOR activity. mTOR inhibition alone or in combination with MAPK pathway inhibition may be a promising therapeutic strategy for this subset of HNSCC tumors.
|
30115483 |
2018 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Therefore, strategies focused on activating EphB3 might be helpful to inhibit tumor growth and enhance sensitivity to PI3K inhibitors in HNSCC.<i></i>.
|
29970482 |
2018 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this study we investigated the activity of PF-04691502, an orally active ATP-competitive, dual inhibitor of PI3K and mTOR, in combination with a clinically relevant fractionated radiation treatment in two contrasting, well characterized, low passage HNSCC models.
|
28823407 |
2017 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Combined treatment with cetuximab and MM-121 blocked EGFR and HER3 activities and inhibited the PI3K/AKT and ERK signaling pathways and HNSCC cell growth more effectively than each antibody alone.
|
27358485 |
2017 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phosphatidylinositol 3-kinase (PI3K) pathway activation in squamous cell carcinoma of the head and neck contributes to treatment resistance and disease progression.
|
28131786 |
2017 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our results strongly suggest that cotargeting of EGFR and PI3K is synergistic and induces apoptosis of SCCHN cell lines by inhibiting both axes of the AKT-mTOR pathway and translational regulation of antiapoptotic Bcl-2 proteins.
|
28119490 |
2017 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results can serve as a preclinical rationale for innovative treatments combining PI3K inhibition with anti-EGFR therapies and irradiation in patients with HNSCC.
|
27507562 |
2017 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this article, we review the genetic alterations reported in the pathway pertinent to HNSCC, various agents in development targeting various mediators of the pathway, results from clinical trials, and remaining challenges in the development of PI3K pathway inhibitors.
|
28108737 |
2017 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma.
|
28194032 |
2017 |
Squamous cell carcinoma of the head and neck
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Hence, we investigated the therapeutic efficacy of inhibiting PI3K with GDC-0032, a PI3K inhibitor with potent activity against p110α, in combination with radiation in HNSCC.
|
26589432 |
2016 |
Squamous cell carcinoma of the head and neck
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The phosphatidylinositol 3-kinase (PI3K) pathway regulates a wide range of cellular processes crucial for tumorigenesis, and PIK3CA amplification and mutation are among the most common genetic alterations in human HNSCC.
|
26876212 |
2016 |
Squamous cell carcinoma of the head and neck
|
0.100 |
Biomarker
|
disease |
BEFREE |
Increasing evidence indicates that both the phosphatidylinositol-3-kinase (PI3K)-Akt-mammalian target of Rapamycin (mTOR) and the nuclear factor-kappa B (NF-κB) are constitutively active and contribute to aggressive HNSCC downstream of EGFR.
|
26895469 |
2016 |